Biotie Therapies - Changes board/management/auditors

David Cook appointed Chief Financial Officer of Biotie

BIOTIE THERAPIES CORP.           STOCK EXCHANGE RELEASE             2 January
2013 at 1:40 p.m

David Cook appointed Chief Financial Officer of Biotie

David Cook, (age 45), has been appointed Chief Financial Officer (CFO) of Biotie
Therapies Corp., effective February 25, 2013. He will become a member of the
Group's management team and will report to Timo Veromaa, President and Chief
Executive Officer. David will be based at the Company's headquarters in Turku,
Finland. Kristian Rantala, current interim CFO, will resume his prior duties as
Vice President, Finance and Administration, Finland.

David Cook, a British native, has extensive industry expertise in life science
enterprises in finance, strategy, investor relations and M&A. Previously David
was CFO, International, of Jazz Pharmaceuticals, Inc., a NASDAQ listed company
and before this CFO of EUSA Pharma Inc., which was acquired by Jazz
Pharmaceuticals in mid-2012. Before joining EUSA David was Group Financial
Controller at Zeneus Pharma Limited and prior to that worked for
PricewaterhouseCoopers in the United Kingdom and Australia. David is a qualified
chartered accountant and graduated from the University of Oxford with a degree
in Chemistry.

Timo Veromaa, CEO of Biotie:"I am very pleased that David is joining Biotie's management team and we look
forward to his contributions to the growth of the group. As Biotie continues to
mature as a company, David's extensive experience in building profitable biotech
businesses will be extremely valuable."

Turku, 2 January 2013

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

www.biotie.com

ABOUT BIOTIE

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post-traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck
A/S, has on 14 December 2012 received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
recommending marketing authorization of Selincro(TM) for the reduction of
alcohol consumption in adult patients with alcohol dependence who have a high
level of alcohol consumption. In addition, Biotie has a strategic collaboration
with UCB Pharma S.A. covering tozadenant which has successfully completed a
Phase 2b study in 420 patients with advanced Parkinson's disease. Biotie shares
are listed on NASDAQ OMX Helsinki Ltd.


[HUG#1667803]